Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2026-06-12 18:04:56 ET · period of report 2026-06-10 · accession 0001672659-26-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-12 18:04 | 2026-06-10+ | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $4.88 | +8,519 | 69.8K | +14% | +$41.6K |
| DMT | 2026-06-12 18:04 | 2026-06-10+ | MLYS | Rodman David Malcom | Chief Medical Off | S - Sale+OE | $24.20 | -8,519 | 63.4K | -12% | -$206.2K |
| DMT | 2026-06-12 18:04 | 2026-06-10+ | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.00 | -8,519 | 6,349 | -57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-10 | M | A | 2,170 | $16.00 | 65,613 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| 2 | Common | Common Stock | 2026-06-10 | S | D | 2,170 | $25.00 | 63,443 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| 3 | Common | Common Stock | 2026-06-12 | M | A | 6,349 | $1.08 | 69,792 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| 4 | Common | Common Stock | 2026-06-12 | S | D | 6,349 | $23.93 | 63,443 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.02. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
| 5 | Derivative | Stock Option | 2026-06-10 | M | D | 2,170 | $0.00 | 17,365 | D | $16.00 · — to 2033-02-09 | 2,170 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. (F3) The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. |
| 6 | Derivative | Stock Option | 2026-06-12 | M | D | 6,349 | $0.00 | 6,349 | D | $1.08 · — to 2032-07-11 | 6,349 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. (F3) The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. |